Investment Summary |
|
|---|---|
| Date | 2007-01-01 |
| Target | ADMA Biologics |
| Sector | Life Science |
| Investor(s) | Aisling Capital |
| Deal Type | PIPE |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2000 |
| PE ASSETS | 1.8B USD |
| Size | Large |
| Type | Sector Focused |
Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 9 of 56 |
| Sector: Life Science M&A | 8 of 42 |
| Type: PIPE M&A Deals | 1 of 12 |
| State: New Jersey M&A | 1 of 5 |
| Country: United States M&A | 9 of 52 |
| Year: 2007 M&A | 2 of 8 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-01-01 |
NextWave Pharmaceuticals
Cupertino, California, United States NextWave Pharmaceuticals is a specialty pharmaceutical company developing extended release OTC and prescription products for children and adults. NextWave Pharmaceuticals was founded in 2005 and is based in Cupertino, California. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-01-25 |
Catalent
Somerset, New Jersey, United States Catalent is a provider of solutions for drugs, biologics and consumer health products. Among its core offerings, it develops and manufactures oral and sterile medication in nearly all dosage forms, holds patents for softgel (e.g. “Liqui-Caps” and “Vegicaps”) and Zydis fast-dissolve technologies used in many popular prescription and over-the-counter medicine. Catalent was founded in 2007 and is based in Somerset, New Jersey. |
Buy | $3.3B |
